<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054184</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-PGT302</org_study_id>
    <secondary_id>CDR0000269907</secondary_id>
    <secondary_id>CWRU-CTI-1503</secondary_id>
    <nct_id>NCT00054184</nct_id>
  </id_info>
  <brief_title>Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer</brief_title>
  <official_title>CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more&#xD;
      effective than docetaxel in treating non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel&#xD;
      with that of docetaxel in treating patients who have progressive non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of polyglutamate paclitaxel (CT-2103) vs docetaxel as second-line&#xD;
           therapy, in terms of duration of overall survival, in patients with progressive&#xD;
           non-small cell lung cancer.&#xD;
&#xD;
        -  Compare the safety and toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the disease control (stable disease maintained for at least 12 weeks, partial&#xD;
           response, or complete response) and progression-free survival of patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare the improvement in lung cancer symptoms in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the frequency of grade 3 and 4 neurotoxicity, edema, alopecia, and side effects&#xD;
           related to corticosteroids in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the percentage of patients who receive at least 4 courses of study treatment.&#xD;
&#xD;
        -  Compare the response rate in patients with measurable disease treated with these&#xD;
           regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to stage (IV vs other), performance status (0 or 1 vs 2), start of front-line&#xD;
      chemotherapy from randomization (less than 16 weeks vs at least 16 weeks), gender, and prior&#xD;
      taxane therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel IV over 1 hour on day 1. In both arms, courses repeat&#xD;
           every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 3 weeks and then every 8 weeks thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 840 patients (420 per treatment arm) will be accrued for this&#xD;
      study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">January 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saftey</measure>
    <time_frame>Baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Basline to EOS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel poliglumex</intervention_name>
    <arm_group_label>Study drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Documented clinical or radiologic disease progression on or after initial systemic&#xD;
             therapy&#xD;
&#xD;
               -  Must have received 1 prior platinum-based systemic therapy for NSCLC&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell&#xD;
             histology&#xD;
&#xD;
          -  Brain metastases allowed provided patient received prior standard antitumor therapy&#xD;
             for CNS metastases (e.g., whole brain radiotherapy, stereotactic radioablation, or&#xD;
             surgery) and the following conditions are met:&#xD;
&#xD;
               -  No prior systemic chemotherapy as a radiosensitizer combined with radiotherapy&#xD;
&#xD;
               -  Obtained stable neurologic function at least 2 weeks before study entry&#xD;
&#xD;
               -  Off steroid therapy or on a tapering regimen&#xD;
&#xD;
               -  Recovered from prior therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Al least 16 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  AST or ALT no greater than 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No evidence of cardiac conduction abnormalities (e.g., bundle branch block or heart&#xD;
             block) unless cardiac status stable for the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of unstable neurological symptoms in the past 4 weeks (2 weeks for&#xD;
             neurological symptoms due to brain metastases)&#xD;
&#xD;
          -  No intolerance to excipients of polyglutamate paclitaxel (e.g., poly-L-glutamic acid,&#xD;
             poloxamer 188, dibasic sodium phosphate, or monobasic sodium hydroxide)&#xD;
&#xD;
          -  No other unstable medical conditions&#xD;
&#xD;
          -  No clinically significant active infection&#xD;
&#xD;
          -  No neuropathy greater than grade 1&#xD;
&#xD;
          -  No other concurrent primary malignancy except carcinoma in situ or nonmelanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  No circumstance that would preclude study completion or follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior polyglutamate paclitaxel&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  More than 2 weeks since prior treatment for NSCLC&#xD;
&#xD;
          -  More than 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent systemic antitumor therapy&#xD;
&#xD;
          -  No concurrent amifostine&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Garrison</last_name>
    <role>Study Chair</role>
    <affiliation>PPD, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Consultants, Incorporated</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group - Springdale</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Incorporated</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Hematology/Oncology Medical Associates</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Care, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904-2007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Hematology/Oncology Medical Group</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Oncology and Hematology Associates</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Oncology Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of theTreasure Coast - Port St. Lucie</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Hematology-Oncology</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078-6782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gross Point Medical Center</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Kentucky Hematology/Oncology Group</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Pikeville</city>
        <state>Kentucky</state>
        <zip>41501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Oncology, Incorporated</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Specialists</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807-7877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Cancer Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Howell</city>
        <state>New Jersey</state>
        <zip>07731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology-Hematology Consultants, Limited</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Associates, PC</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Oncology Specialist, II, PLLC</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research Services</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center - Canton Office</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hematology Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Hematology-Oncology, P.A.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri County Oncology Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732-1119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santee Hematology Oncology</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Regional Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Hematology and Oncology, Incorporated</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Care P.C.</name>
      <address>
        <city>Richlands</city>
        <state>Virginia</state>
        <zip>24641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Washington Medical Group</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Paclitaxel poliglumex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

